COVID-19 substantially raises the risk of stroke, particularly ischemic stroke caused by blood clots blocking arteries to the brain. One case-control study found that after adjusting for age, sex, and typical risk factors, COVID-19 infection was independently associated with roughly a fourfold increase in the odds of acute ischemic stroke. The relationship turned out to be more complex and more alarming than the early pandemic reports suggested, with unusual patterns of stroke showing up in younger patients without the traditional warning signs.
How Much COVID Raises Stroke Risk
Among the earliest quantitative evidence was a study comparing patients admitted with ischemic stroke to matched controls: about 46% of the stroke group had COVID-19, versus about 18% of controls. After statistical adjustment, COVID-19 carried an odds ratio of roughly 3.9 for acute ischemic stroke.1PubMed Central. COVID-19 Is an Independent Risk Factor for Acute Ischemic Stroke A separate comparison against influenza found an even starker gap: after adjusting for age, sex, and race, the likelihood of ischemic stroke with COVID-19 was about seven and a half times higher than with influenza.2PubMed Central. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza Among hospitalized COVID-19 patients, ischemic stroke occurred in roughly 1% to 2% of cases, depending on the cohort studied.3PubMed Central. Incidence and Features of Acute Ischemic Stroke in Patients Hospitalized with COVID-19: A Multi-center Study in Turkey That may sound small, but across millions of infections it translates to an enormous absolute number of strokes that would not have occurred otherwise.
Not every study agreed on the magnitude, though. A large Veterans Affairs analysis comparing hospitalized COVID-19 patients with hospitalized influenza patients found that the adjusted risk of arterial thromboembolism (which includes stroke) was not significantly elevated during either the pre-vaccine or vaccine-availability periods.4JAMA. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients The discrepancy likely reflects differences in study populations, time periods, and how broadly “arterial thromboembolism” was defined. The weight of the evidence still points clearly toward COVID-19 carrying a meaningful stroke risk, but the exact multiplier depends on the comparison group and the era of the pandemic.
How COVID Triggers Stroke
The virus does not simply clog arteries in the way high cholesterol does. Instead, SARS-CoV-2 sets off a chain of events in the blood and blood-vessel lining that makes clots far more likely to form. Patients who developed strokes during COVID-19 often had markedly elevated D-dimer levels and fibrinogen along with low platelet counts, all hallmarks of a hypercoagulable state where the blood clotting system is in overdrive.5PubMed Central. COVID‑19 and ischemic stroke: Mechanisms of hypercoagulability Clinical case series confirmed hypercoagulability as a central mechanism in COVID-19-related strokes, occurring even in patients without respiratory failure.6PubMed Central. COVID-19 Disease and Hypercoagulability Leading to Acute Ischemic Stroke
The damage extends to the blood-vessel walls themselves. The virus uses ACE2 receptors to enter cells, and these receptors are present in brain blood vessels. Endothelial cells, which line the inside of blood vessels and help form the blood-brain barrier, become dysfunctional during infection. That dysfunction, combined with the inflammatory response and clotting abnormalities, creates a perfect environment for clots to form in brain vessels.7PubMed Central. Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated? People with diabetes or smoking history may be even more vulnerable because both conditions increase ACE2 expression in brain blood vessels, potentially giving the virus more points of entry.8PubMed Central. Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke
Cardioembolism also plays a role. COVID-19 can damage the heart directly, causing conditions that allow clots to form in the cardiac chambers and then travel to the brain. The inflammatory storm triggered by the virus contributes to this cardiac injury, and patients with both cardiac complications and stroke during COVID had substantially worse outcomes.9ScienceDirect / Elsevier (Journal of Stroke and Cerebrovascular Diseases). Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke
Strokes in Younger Patients Without Typical Risk Factors
One of the most unsettling early findings was a surge of large-vessel strokes in young adults. During a two-week peak in New York City, five patients under 50 who tested positive for SARS-CoV-2 presented with large-vessel stroke. Some had no vascular risk factors at all. That represented a sevenfold increase over the same period the prior year.10PubMed Central. COVID-19 related stroke in young individuals A broader multicenter series of 20 COVID-19 patients with acute ischemic stroke found that 75% had large-vessel occlusion. The average age was just 46.5 years, 93% were male, and 60% had no traditional cardiovascular risk factors.11American Journal of Neuroradiology. Characteristics of Large-Vessel Occlusion Associated with COVID-19 and Ischemic Stroke
This pattern stood out because in normal circumstances, large-vessel stroke overwhelmingly affects older adults with years of vascular disease buildup. COVID-19 seemed capable of short-circuiting that timeline through sheer inflammatory and clotting force, producing the kind of devastating large-artery blockages you would expect in someone decades older. Some of these young patients had only mild respiratory symptoms, or none at all, before the stroke hit.
Ischemic Versus Hemorrhagic Stroke
Both ischemic stroke (caused by a blocked vessel) and hemorrhagic stroke (caused by a burst vessel) occur in COVID-19 patients, but they are not equally common. A systematic review and meta-analysis covering tens of thousands of patients estimated that ischemic stroke accounted for roughly 72% of COVID-related strokes and hemorrhagic stroke for about 28%.12PubMed Central. Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis – a systematic review and meta-analysis The pooled prevalence of ischemic stroke among hospitalized COVID-19 patients was about 1.1%, while hemorrhagic stroke came in at about 0.5%.
The hemorrhagic side has its own mechanism. Most patients who suffered bleeding strokes had underlying hypertension or diabetes. The virus likely compounds those existing risks by further dysregulating the ACE2 pathway, which can elevate blood pressure and weaken cerebral blood vessel walls.13PubMed Central. Potential mechanisms of hemorrhagic stroke in elderly COVID-19 patients So while the hypercoagulable state drives ischemic strokes, the virus also has a separate pathway for triggering bleeds, particularly in older patients with chronic conditions.
Why COVID-Related Strokes Have Worse Outcomes
Having COVID-19 at the time of a stroke does not just raise the risk of having one; it makes the stroke itself more damaging. In a global registry comparing matched groups, patients with COVID-19-associated ischemic stroke had more than four times the odds of dying compared with ischemic stroke patients without COVID. They also had significantly higher rates of severe disability at discharge.14PubMed. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry A large analysis of over 27,000 patients confirmed the trend, showing that COVID-19 was associated with worse discharge outcomes, including higher rates of death or discharge to somewhere other than home.15PubMed Central. Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients
Mortality figures illustrate the gap starkly. In one study, nearly half of stroke patients with active COVID-19 infection died, compared with about a quarter of those who had previously tested positive but were no longer actively infected, and about 17% of stroke patients with no COVID-19 history.16Exploration of Neuroprotective Therapy. Higher mortality in stroke patients with active COVID-19 infection Multiple factors converge to produce these worse outcomes: the virus may make clots larger and harder to dissolve, systemic inflammation worsens brain injury, and patients are often sicker overall from the respiratory and cardiac effects of the infection itself.
Treating Stroke During COVID-19
Standard acute stroke treatments, intravenous clot-dissolving drugs (tPA) and mechanical clot removal (thrombectomy), remained the front-line approaches during the pandemic. The key question was whether COVID-19 made these procedures less safe or less effective.
For tPA, a multicenter study found that after adjusting for confounding factors, COVID-19 patients who received the drug did not have a significantly higher rate of disability, in-hospital death, or hemorrhagic transformation compared with non-COVID patients.17PubMed. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative However, another study found that COVID-19 patients were more likely to have hemorrhagic transformation after tPA, even though the treatment was still considered safe and effective overall.18PubMed Central. Recombinant tissue plasminogen activator (rTPA) management for first onset acute ischemic stroke with covid -19 and non-covid -19 patients The picture, in other words, is mixed: tPA appears usable in COVID-19 patients, but clinicians needed to watch more carefully for bleeding complications.
For thrombectomy, the technical success rate stayed high. In one multicenter series of 111 COVID-19 patients, successful reopening of the blocked vessel was achieved in about 87% of cases.19Journal of NeuroInterventional Surgery. Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases But even when doctors successfully cleared the clot, COVID-19 patients tended to do worse clinically than non-COVID patients with similarly successful procedures. The accumulating evidence indicated a negative impact of the virus on outcomes regardless of whether the blood vessel was reopened on time.20PubMed Central. Mechanical Thrombectomy Outcomes in COVID-19 Patients With Acute Ischemic Stroke: A Narrative Review This suggests that the systemic inflammation and ongoing clotting abnormalities from the virus continue to cause damage even after the initial blockage is cleared.
Pandemic Delays in Stroke Care
Beyond the biological effects of the virus, the pandemic itself slowed down stroke treatment. Time is everything in stroke care, and even a few minutes of delay can mean more brain tissue lost. During lockdown periods, the time from hospital door to tPA administration rose from a median of 50 minutes to 65 minutes, and the time from door to thrombectomy puncture increased from 120 to 160 minutes.21PubMed Central. The impact of COVID-19 pandemic on treatment delay and short-term neurological functional prognosis for acute ischemic stroke during the lockdown period The delays were driven by the need for additional protective equipment, COVID-19 screening, extra consultations, and chest CT scans.
A U.S. multicenter study confirmed these delays, finding that patients treated during COVID-19 had significantly lower odds of receiving tPA within 60 minutes of arrival. The bottleneck appeared to be the time between brain imaging and the actual drug injection, likely reflecting the extra steps required to handle potentially infectious patients.22PubMed Central. Influence of the COVID-19 Pandemic on Treatment Times for Acute Ischemic Stroke: The Society of Vascular and Interventional Neurology Multicenter Collaboration Added to this were patients who delayed coming to the emergency room in the first place, either fearing COVID exposure or unable to recognize stroke symptoms while dealing with infection-related illness. The result was a double penalty: COVID made strokes more likely and more severe, and the pandemic simultaneously made getting treated harder and slower.
Anticoagulation During COVID Hospitalization
Because clotting is such a central driver of COVID-related vascular events, researchers tested whether giving hospitalized COVID patients stronger blood thinners could prevent strokes and other clot-related problems. The COVID-PACT trial compared full-dose anticoagulation against the standard lower preventive dose in critically ill patients and found that full-dose treatment roughly cut the rate of blood-clot events in half.23PubMed Central. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT
A systematic review and meta-analysis found that therapeutic-dose anticoagulation significantly reduced the incidence of venous blood clots compared with prophylactic dosing, but it was not associated with a reduction in arterial clot events like stroke specifically.24PubMed Central. Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis That distinction matters. Stronger blood thinners clearly helped prevent blood clots in veins and lungs, but the evidence for preventing strokes specifically was less clear. Meanwhile, higher doses of blood thinners carry the obvious downside of increased bleeding risk, so the decision had to be individualized based on how sick the patient was and their pre-existing bleeding risk.
Vaccination and Stroke Risk
Early in the vaccine rollout, reports of rare blood-clotting events raised concern about a possible link between COVID-19 vaccines and stroke. The data that accumulated since then has been reassuring. A nationwide study in Qatar found a small, transient increase in stroke incidence within 21 days of vaccination, but the events were exceedingly rare, and the excess risk was substantially lower than the stroke risk associated with actual COVID-19 infection.25PubMed. Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar
A Danish study of 4.6 million individuals made the comparison directly. People who tested positive for SARS-CoV-2 had four times the odds of stroke compared with people who had been vaccinated, along with far higher risks of pulmonary embolism and deep vein thrombosis.26European Heart Journal. Risk of acute myocardial infarction, stroke and thromboembolism following COVID-19 vaccination compared to testing positive for COVID-19 infection: a nationwide cohort study of 4.6 mio individuals A statewide analysis in the U.S. further underscored this: among people who happened to have concurrent COVID-19 infection at the time of vaccination, the stroke risk jumped dramatically, with an eightfold increase in ischemic stroke odds. But this risk came from the infection, not the vaccine.27PubMed Central. Factors associated with stroke after COVID-19 vaccination: a statewide analysis The overall message is that while no medical intervention is entirely without risk, the stroke risk from COVID-19 infection dwarfs any risk posed by vaccination.
Socioeconomic Disparities in Outcomes
The pandemic did not affect all stroke patients equally. A nationally representative U.S. analysis focused on hemorrhagic stroke found that before the pandemic, mortality rates for brain bleeding were actually declining by about 1% per month. During the pandemic, that trend reversed, with mortality climbing by about 2% per month relative to the earlier trajectory. But the deterioration was not uniform. Among patients living in low-income zip codes, mortality jumped by roughly 4% per month relative to pre-pandemic trends. Among patients in high-income zip codes, there was no significant change.28PubMed Central. Poor haemorrhagic stroke outcomes during the COVID-19 pandemic are driven by socioeconomic disparities: analysis of nationally representative data
These disparities likely reflect several overlapping factors: unequal access to emergency care, higher rates of untreated chronic conditions like hypertension in lower-income communities, reduced availability of neurosurgical and neurological specialty services in under-resourced hospitals, and the general pandemic strain on healthcare systems that disproportionately affected safety-net hospitals. The finding is a reminder that the stroke-COVID connection was not just a biological phenomenon but a social one.
The Blood-Brain Barrier and Neuroinflammation
Stroke is the most dramatic brain complication of COVID-19, but research suggests the virus creates a broader state of neuroinflammation that may contribute to stroke risk and worsen its damage. Using a laboratory model that mimics the lung-brain connection, researchers found that even without the virus directly invading brain tissue, inflammatory signals from infected lung cells caused endothelial dysfunction, pericyte detachment, and activated inflammatory pathways in brain cells.29PubMed Central. Blood–brain barrier injury and neuroinflammation induced by SARS-CoV-2 in a lung–brain microphysiological system In other words, the lungs do not need to send virus to the brain. They send inflammatory signals that are enough to damage the blood-brain barrier on their own.
This has implications beyond acute stroke. A weakened blood-brain barrier allows inflammatory molecules and immune cells to enter brain tissue more freely, potentially extending brain damage after a stroke and contributing to the cognitive symptoms many COVID survivors experience. Research on immune cells in the brain during COVID-19 has explored the role of innate immune activation in driving these neurological effects.30PubMed Central. Neuroinflammation and COVID-19 How much of the long-term neurological toll of COVID-19 stems from this inflammation versus from the strokes themselves is still being worked out.
When It Happens to Children
Stroke is rare in children under any circumstances, and COVID-related stroke in kids rarer still. But it has happened, and the mechanism is distinct from what occurs in adults. Children do not typically develop the same immediate hypercoagulable state. Instead, some children who have had COVID-19, even mild or asymptomatic cases, develop Multisystem Inflammatory Syndrome in Children (MIS-C) weeks later. This delayed immune overreaction can cause cardiac dysfunction, and in rare cases, the combination of inflammation and impaired heart function leads to clots that travel to the brain.
Case reports have documented large-vessel ischemic stroke in previously healthy adolescents with MIS-C. The pathophysiology appears to involve a delayed immune-mediated inflammatory response rather than the direct viral invasion that drives strokes in adults.31Pediatric Neurology. Clinical Observation Acute Large Vessel Ischemic Stroke in Patients With COVID-19–Related Multisystem Inflammatory Syndrome In one case, a two-year-old with MIS-C developed ischemic infarcts in multiple brain territories and required emergency surgery to relieve brain swelling.32Pediatric Neurosurgery. Post-COVID-19 Multisystem Inflammatory Syndrome-Related Cerebral Infarction in a Pediatric Patient Managed with Decompressive Craniectomy These cases remain extremely rare, but they illustrate that COVID-related stroke is not exclusively an adult problem and that the pathway to stroke in children follows its own immunological logic.